Climb Bio (NASDAQ:CLYM) Sets New 12-Month High – Should You Buy?

Climb Bio, Inc. (NASDAQ:CLYM)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $18.33 and last traded at $17.84, with a volume of 1198892 shares traded. The stock had previously closed at $16.40.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Phase 2 progress in China: Climb Bio advanced its Phase 2 trial in China, a development that may strengthen confidence in its pipeline. However, the accompanying analysis questioned whether this progress is already reflected in the valuation. Climb Bio Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: More favorable earnings outlook: HC Wainwright raised its estimated loss for fiscal 2026 to $0.76 per share from $0.93, narrowed its projected Q3 loss to $0.20 from $0.23, and reduced its Q4 loss estimate to $0.19 from $0.22. Its FY2027 loss estimate also improved slightly to $0.98 from $0.99 per share.
• Positive Sentiment: Buy rating and upside target: HC Wainwright reiterated a “Buy” rating and a $24 price target, implying meaningful potential upside from recent trading levels. The improved forecasts are more optimistic than some consensus estimates.
• Neutral Sentiment: Heavy call-option activity: Traders purchased 3,024 call options on August 26, roughly 740% above the average volume. This indicates elevated speculative interest and may reflect bullish expectations, although options activity alone does not confirm a sustained move higher.
• Negative Sentiment: Unusually large put buying: Investors purchased 7,091 put options on August 27, approximately 1,046% above typical volume. The sharp increase points to heightened downside hedging or bearish speculation and likely contributed to pressure on CLYM.

Analysts Set New Price Targets

CLYM has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Friday, July 17th. Wall Street Zen upgraded Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Chardan Capital assumed coverage on Climb Bio in a research report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price objective for the company. Guggenheim initiated coverage on Climb Bio in a report on Monday, June 8th. They set a “buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright lifted their target price on Climb Bio from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $23.08.

Climb Bio Trading Down 6.3%

The company has a market cap of $865.05 million, a P/E ratio of -18.14 and a beta of 0.08. The business has a 50 day moving average price of $13.76 and a 200-day moving average price of $10.44.

Climb Bio (NASDAQ:CLYM) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.03. On average, sell-side analysts expect that Climb Bio, Inc. will post -0.82 earnings per share for the current year.

Institutional Trading of Climb Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System bought a new stake in shares of Climb Bio during the 2nd quarter worth about $82,000. Braidwell LP grew its stake in Climb Bio by 102.6% in the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after buying an additional 1,569,352 shares during the last quarter. Wellington Management Group LLP bought a new position in Climb Bio in the 2nd quarter valued at about $1,262,000. Bank of America Corp DE bought a new position in Climb Bio in the 2nd quarter valued at about $335,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Climb Bio during the second quarter worth approximately $10,727,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.